Abiopharma

Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5

Compass Pathways - Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

New Form RW - Scilex Holding Co Filed: 2026-01-06 AccNo: 0001193125-26-003394 Size: 9 KB

New Form QUALIF - Dare Bioscience, Inc. Filed: 2026-01-05 AccNo: 9999999994-26-000005 Size: 1 KB

BioNTech SE (BNTX) Files Form 6-K

(99% Neutral) GERON CORP (GERN) Reports Q1 2026 Financial Results

CureVac (CVAC) Files Form 6-K

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

Grey symbol attribute type Security_Name was changed. Previous value: RZOLV TECHNOLOGIES INC. New value: HISTOGEN INC.

Final approval of ANDA #ANDA #219773 for PHENYTOIN SODIUM. Decision date: 01/02/2026

Labeling changes approved for AMNEAL PHARMS. Active ingredient: CARBAMAZEPINE. Decision date: 01/05/2026

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016